HAL Blue-light Cystoscopy in High-risk Nonmuscle-invasive Bladder Cancer—Re-TURBT Recurrence Rates in a Prospective, Randomized Study

Geavlete, B.; Jecu, M.; Multescu, R.; Georgescu, D.; Geavlete, P.

doi:10.1016/j.urology.2010.02.067

Cited by 56 publications

(28 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The detection rate for Ta lesions also appears to be better for PDD, that is 94% to 97% vs 83% to 88% for WLC alone. 27,28 For T1 disease 2 groups reported improved detection with PDD, that is about 10% greater than for WLC. Others noted similar detection rates.…”

Section: Resultsmentioning

confidence: 96%

“…Others noted similar detection rates. 27–29 Few groups have described the detection of invasive disease but Schmid-bauer et al suggested that the detection rate is similar. 28 …”

Section: Resultsmentioning

confidence: 99%

“…26 Subgroup analysis of patients with a solitary papillary tumor less than 3 cm vs those with multiple tumors or tumors greater than 3 cm revealed a decreased residual disease rate at second look TUR in each group with initial PDD guided TUR but the difference was only significant for those who presented with multiple or large tumors. 27 All study patients received mitomycin postoperatively, potentially qualifying the beneficial effects of PDD alone for decreasing the recurrence rate.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

New Optical Imaging Technologies for Bladder Cancer: Considerations and Perspectives

2012

View full text Add to dashboard Cite

Purpose Bladder cancer presents as a spectrum of different diatheses. Accurate assessment for individualized treatment depends on initial diagnostic accuracy. Detection relies on white light cystoscopy accuracy and comprehensiveness. Aside from invasiveness and potential risks, white light cystoscopy shortcomings include difficult flat lesion detection, precise tumor delineation to enable complete resection, inflammation and malignancy differentiation, and grade and stage determination. Each shortcoming depends on surgeon ability and experience with the technology available for visualization and resection. Fluorescence cystoscopy/photodynamic diagnosis, narrow band imaging, confocal laser endomicroscopy and optical coherence tomography address the limitations and have in vivo feasibility. They detect suspicious lesions (photodynamic diagnosis and narrow band imaging) and further characterize lesions (optical coherence tomography and confocal laser endomicroscopy). We analyzed the added value of each technology beyond white light cystoscopy and evaluated their maturity to alter the cancer course. Materials and Methods Detailed PubMed® searches were done using the terms “fluorescence cystoscopy,” “photodynamic diagnosis,” “narrow band imaging,” “optical coherence tomography” and “confocal laser endomicroscopy” with “optical imaging,” “bladder cancer” and “urothelial carcinoma.” Diagnostic accuracy reports and all prospective studies were selected for analysis. We explored technological principles, preclinical and clinical evidence supporting nonmuscle invasive bladder cancer detection and characterization, and whether improved sensitivity vs specificity translates into improved correlation of diagnostic accuracy with recurrence and progression. Emerging preclinical technologies with potential application were reviewed. Results Photodynamic diagnosis and narrow band imaging improve nonmuscle invasive bladder cancer detection, including carcinoma in situ. Photodynamic diagnosis identifies more papillary lesions than white light cystoscopy, enabling more complete resection and fewer residual tumors. Despite improved treatment current data on photodynamic diagnosis do not support improved high risk diathetic detection and characterization or correlation with disease progression. Prospective recurrence data are lacking on narrow band imaging. Confocal laser endomicroscopy and optical coherence tomography potentially grade and stage lesions but data are lacking on diagnostic accuracy. Several emerging preclinical technologies may enhance the diagnostic capability of endoscopic imaging. Conclusions New optical imaging technologies may improve bladder cancer detection and characterization, and transurethral resection quality. While data on photodynamic diagnosis are strongest, the clinical effectiveness of these technologies is not proven. Prospective studies are needed, particularly of narrow band imaging, confocal laser endomicroscopy and optical coherence tomography. As each technology matures and new ones emerg...

show abstract

Section: Resultsmentioning

confidence: 96%

“…Others noted similar detection rates. 27–29 Few groups have described the detection of invasive disease but Schmid-bauer et al suggested that the detection rate is similar. 28 …”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

New Optical Imaging Technologies for Bladder Cancer: Considerations and Perspectives

2012

View full text Add to dashboard Cite

show abstract

“…[44] . Geavlete et al [45] used HAL in high-risk bladder cancer and reported that at re-resection at 6 weeks, there was a shortterm recurrence rate of 11% with FC versus 31% with WLC alone. Overall, the use of FC can prolong the time to recurrence in NMIBC.…”

Section: Fluorescence Cystoscopy (Fc)mentioning

confidence: 99%

Approaching the optimal transurethral resection of a bladder tumor

Jurewicz

Soloway

2014

Turkish Journal of Urology

View full text Add to dashboard Cite

A complete transurethral resection of a bladder tumor (TURBT) is essential for adequately diagnosing, staging, and treating bladder cancer. A TURBT is deceptively difficult and is a highly underappreciated procedure. An incomplete resection is the major reason for the high incidence of recurrence following initial transurethral resection and thus to the suboptimal care of our patients. Our objective was to review the preoperative, intraoperative, and postoperative considerations for performing an optimal TURBT. The European Association of Urology, Society of International Urology, and The American Urological Association guidelines emphasize a complete resection of all visible tumor during a TURBT. This review will emphasize the various techniques and treatments, including photodynamic cystoscopy, intravesical chemotherapy, and a perioperative checklist, that can be used to help to enable a complete resection and reduce the recurrence rate. A Medline/PubMed search was completed for original and review articles related to transurethral resection and the treatment of non-muscle-invasive bladder cancer. The major findings were analyzed and are presented from large prospective, retrospective, and review studies.

show abstract

“…Photodynamic diagnosis is especially useful for the detection of tiny and flat lesions. The additional detection rate, which cannot detect tumors by conventional white light, is between 10% and 30% . 5‐Aminolevulinic acid‐mediated photodynamic diagnosis for bladder cancer shows improved diagnostic accuracy, as well as an improved recurrence rate, after transurethral resection of bladder tumor.…”

mentioning

confidence: 99%

Editorial Comment from Dr Fukuhara to Intraoperative hypotension caused by oral administration of 5‐aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer

Fukuhara

2019

Int J of Urology

View full text Add to dashboard Cite

HAL Blue-light Cystoscopy in High-risk Nonmuscle-invasive Bladder Cancer—Re-TURBT Recurrence Rates in a Prospective, Randomized Study

Cited by 56 publications

References 27 publications

New Optical Imaging Technologies for Bladder Cancer: Considerations and Perspectives

New Optical Imaging Technologies for Bladder Cancer: Considerations and Perspectives

Approaching the optimal transurethral resection of a bladder tumor

Editorial Comment from Dr Fukuhara to Intraoperative hypotension caused by oral administration of 5‐aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer

Contact Info

Product

Resources

About